Table 1 Baseline characteristics of the study population.
Variables† | Statin naïve; all patients (n = 1429) | LDL-C < 131 mg/dL group (n = 686) | LDL-C ≥ 131 mg/dL group (n = 743) | P value* |
|---|---|---|---|---|
Age (years) | 65.3 ± 11.9 | 67.4 ± 12.0 | 63.3 ± 11.5 | < 0.0001 |
Male | 1113 (77.9%) | 555 (80.9%) | 558 (75.1%) | 0.01 |
BMI (kg/m2) | 24.1 ± 3.5 | 23.9 ± 3.4 | 24.3 ± 3.5 | 0.06 |
Estimated GFR (mL/min/1.73 m2) | 74.1 ± 25.9 | 72.3 ± 32.0 | 75.8 ± 18.5 | < 0.0001 |
Hypertension | 939 (65.7%) | 474 (69.1%) | 465 (62.6%) | 0.01 |
Diabetes mellitus | 398 (27.9%) | 202 (29.5%) | 196 (26.4%) | 0.20 |
Current smoker | 520 (36.4%) | 218 (31.8%) | 302 (40.7%) | < 0.0001 |
Previous myocardial infarction | 76 (5.3%) | 42 (6.1%) | 34 (4.6%) | 0.19 |
Previous revascularization | 86 (6.0%) | 53 (7.7%) | 33 (4.4%) | 0.009 |
Type of index event | 0.20 | |||
STEMI | 768 (53.7%) | 356 (51.9%) | 412 (55.5%) | |
Non-STEMI | 155 (10.8%) | 71 (10.4%) | 84 (11.3%) | |
Unstable angina pectoris | 506 (35.4%) | 259 (37.8%) | 247 (33.2%) | |
Medication | ||||
Beta-blockers | 116 (8.1%) | 76 (11.1%) | 40 (5.4%) | < 0.0001 |
ACEI/ARB | 338 (23.7%) | 207 (30.2%) | 141 (19.0%) | < 0.0001 |
Aspirin | 176 (12.3%) | 114 (16.6%) | 62 (8.3%) | < 0.0001 |
Cholesterol metabolism at baseline (mg/dL) | ||||
Total cholesterol | 213 ± 35.5 | 187 ± 19.3 | 236 ± 31.2 | < 0.0001 |
HDL-cholesterol | 48.4 ± 12.4 | 47.8 ± 12.8 | 48.9 ± 11.9 | 0.02 |
LDL-cholesterol | 138 ± 29.8 | 115 ± 10.1 | 159 ± 25.2 | < 0.0001 |
Triglyceride | 130 ± 71.0 | 123 ± 68.7 | 137 ± 72.4 | < 0.0001 |
High-sensitivity CRP (mg/L) | 8.51 [2.46, 26.1] | 7.86 [2.37, 25.23] | 9.24 [2.50, 27.05] | 0.33 |
Markers of cholesterol absorption/synthesis (µg/L) | ||||
Sitosterol | 2.46 ± 1.57 | 2.18 ± 1.21 | 2.72 ± 1.80 | < 0.0001 |
Lathosterol | 1.96 ± 1.31 | 1.85 ± 1.19 | 2.06 ± 1.41 | 0.007 |
Campesterol | 4.66 ± 2.40 | 4.16 ± 1.93 | 5.12 ± 2.69 | < 0.0001 |
